Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

BACKGROUND: This study aimed to correlate body mass index or biomarkers with the frequency of common adverse events (AEs) with subcutaneous IFN β-1a during treatment titration in patients with relapsing-remitting multiple sclerosis previously naïve to IFN β. METHODS: Eighty-four patients (66.3% fema...

Descripción completa

Detalles Bibliográficos
Autores principales: Muñoz, Delicias, Escartín, Antonio, Dapena, Dolores, Coret, Francisco, Fernández-Uría, Dionisio, Pérez, Domingo, Casanova, Bonaventura, Guijarro-Castro, Cristina, Munteis, Elvira, del-Campo Amigo, María, Pego, Robustiano, Calles, Carmen, García-Rey, César, Monsalve, Nuria, Sánchez-Matienzo, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3710468/
https://www.ncbi.nlm.nih.gov/pubmed/23845043
http://dx.doi.org/10.1186/1471-2377-13-82

Ejemplares similares

Ejemplares similares